Want to see JP:4588 full AI Analyst Report?
4588 Stock Chart & Stats
¥953.00
-¥1.00(-0.20%)
At close: 4:00 PM EST
¥953.00
-¥1.00(-0.20%)
Day’s Range― - ―
52-Week Range¥695.00 - ¥8,000.00
Previous CloseN/A
Volume332.10K
Average Volume (3M)1.39M
Market Cap
¥223.32B
Enterprise Value¥84.23B
Total Cash (Recent Filing)¥3.72B
Total Debt (Recent Filing)¥320.02M
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-81.78
Shares Outstanding29,575,700
10 Day Avg. Volume1,585,640
30 Day Avg. Volume1,387,866
Financial Highlights & Ratios
PEG Ratio-4.72
Price to Book (P/B)8.90
Price to Sales (P/S)1247.26
P/FCF Ratio-18.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageThe lower debt-to-equity ratio indicates comparatively modest leverage and gives the company more balance-sheet flexibility than a heavily indebted biotechnology peer. This can help preserve strategic options while clinical development and commercialization efforts require sustained investment.
Expanded Balance SheetMeaningful growth in equity and total assets provides a broader financial base to support ongoing research, development, and partnership activity. Although losses remain significant, this balance-sheet expansion suggests funding support and capacity that may help sustain operations over the medium term.
Therapeutics Development ModelOncolys operates in a development model centered on novel therapeutics, including biologics and virology-based approaches, with partnership-led commercialization opportunities. If candidates advance successfully, this structure can provide scalable product potential without requiring the company to build every commercial capability alone.
Bears Say
Revenue CollapseThe steep and sustained revenue decline shows that current commercial or milestone-related income is not providing a dependable operating base. Without a major revenue inflection, the company has limited ability to absorb development costs internally, making financial performance highly dependent on future product progress.
Persistent Operating LossesLarge recurring operating losses indicate that expenses substantially exceed the company’s current revenue scale. This weak earnings profile can erode equity over time, restrict reinvestment capacity, and leave profitability dependent on successful development or commercialization of future candidates.
Ongoing Cash BurnPersistent operating and free-cash-flow outflows show that the business is not self-funding its research and development activities. Continued burn increases dependence on external financing or other funding support, which may constrain strategic flexibility and expose shareholders to future dilution risk.
Oncolys BioPharma, Inc. News
4588 FAQ
What was Oncolys BioPharma, Inc.’s price range in the past 12 months?
Oncolys BioPharma, Inc. lowest stock price was ¥695.00 and its highest was ¥8000.00 in the past 12 months.
What is Oncolys BioPharma, Inc.’s market cap?
Oncolys BioPharma, Inc.’s market cap is ¥223.32B.
When is Oncolys BioPharma, Inc.’s upcoming earnings report date?
Oncolys BioPharma, Inc.’s upcoming earnings report date is Nov 06, 2026 which is in 5 days.
How were Oncolys BioPharma, Inc.’s earnings last quarter?
Oncolys BioPharma, Inc. released its earnings results on Aug 07, 2026. The company reported -¥11.87 earnings per share for the quarter.
Is Oncolys BioPharma, Inc. overvalued?
According to Wall Street analysts Oncolys BioPharma, Inc.’s price is currently Overvalued.
Does Oncolys BioPharma, Inc. pay dividends?
Oncolys BioPharma, Inc. does not currently pay dividends.
What is Oncolys BioPharma, Inc.’s EPS estimate?
Oncolys BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncolys BioPharma, Inc. have?
Oncolys BioPharma, Inc. has 29,575,700 shares outstanding.
What happened to Oncolys BioPharma, Inc.’s price movement after its last earnings report?
Oncolys BioPharma, Inc. reported an EPS of -¥11.87 in its last earnings report. Following the earnings report the stock price went up 1.751%.
Which hedge fund is a major shareholder of Oncolys BioPharma, Inc.?
Currently, no hedge funds are holding shares in JP:4588
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncolys BioPharma, Inc.
Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the United States. Its robust pipeline features Telomelysin (OBP-301), an oncolytic adenovirus, currently in Phase II clinical trials for the treatment of gastric, gastroesophageal junction, head and neck, and esophageal cancers, and in Phase I trials for hepatocellular carcinoma. Other key developments include OBP-702, a telomerase-specific oncolytic adenovirus in preclinical stages for solid tumors; OBP-2011, also preclinical, targeting SARS-CoV-2 infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed Phase IIb clinical trials for HIV; and OBP-801, a histone deacetylase inhibitor, which is in Phase I clinical trials for solid tumors and preclinical assessment for ophthalmic applications. Additionally, the company is advancing TelomeScan (OBP-401 and OBP-1101), a cancer detection drug designed to identify living circulating tumor cells in cancer patients' blood. Oncolys BioPharma also offers diagnostic medications and inspection services. The company boasts various licensing and collaborative agreements with institutions such as Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Founded in 2004, Oncolys BioPharma Inc. is based in Tokyo, Japan.